Physician profile
Brian D Phipps
NPI 1710085287
$2,834.69
in general payments reported to CMS, 2019-2025
24 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,752 · 2020: $364 · 2021: $51.22 · 2022: $104 · 2023: $137 · 2024: $274 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $562.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $498.95 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $315.29 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $307.95 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $300.14 | 2019-2025 | |
| Amarin Pharma, INC. | $263.39 | 2019-2020 | |
| Lilly USA, LLC | $190.43 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $177.03 | 2019-2020 | |
| Amgen INC. | $92.44 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $91.37 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $83.75 | 2019 | |
| Astellas Pharma US INC | $73.40 | 2019-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.33 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.34 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $61.10 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $47.53 | 2019-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31.37 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $29.33 | 2019 | |
| Genentech USA, INC. | $26.51 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.24 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $25.04 | 2019 | |
| Exact Sciences Corporation | $21.97 | 2024 | Cologuard Collection Kit |
| Metuchen Pharmaceuticals | $15.08 | 2019 | |
| Medtronic Minimed, INC. | $12.64 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Phipps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.